ライフサイエンスコーパス: leukotriene receptor

1 actor that acts on plasma membrane cysteinyl leukotriene receptors.

2 Our data show that LTB4, via its receptor B leukotriene receptor 1 (BLT1) and Galphai signaling, inc

3 B4 act through activation of its receptor, B leukotriene receptor 1 (BLT1).

4 ease in cell-surface expression of cysteinyl leukotriene receptor 1 (CysLT1) as determined by flow cy

5 rthermore, LTD4 plus PGE2, through cysteinyl leukotriene receptor 1 (CysLT1R) and E-prostanoid recept

6 thma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R).

7 " neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced TNF, CCL2,

8 )2 cells might selectively express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA.

9 We functionally assessed cysteinyl leukotriene receptor 1 protein (CysLT(1)) expression usi

10 and montelukast, an antagonist of cysteinyl leukotriene receptor 1.

11 tory cells and their expression of cysteinyl leukotriene receptors 1 and 2 (CysLT(1) and CysLT(2)) an

12 genic small molecule antagonist of cysteinyl leukotriene receptors 1 and 2 (CysLT1 and CysLT2).

13 get VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1-2) at micromolar I

14 B leukotriene receptor-1 (BLT-1), the primary LTB4 recepto

15 d a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitut

16 Stimulation of the cysteinyl leukotriene receptor activated CRAC channels and evoked

17 stain cytoplasmic Ca(2+) signaling following leukotriene receptor activation both by refilling the Ca

18 fter rundown of the Ca(2+) signals following leukotriene receptor activation, stimulation of P2Y rece

19 ukast (an antagonist of the type 1 cysteinyl leukotriene receptor) also inhibited E. coli invasion of

20 e as a dualistic uracil nucleotide/cysteinyl leukotriene receptor and by others as inactive toward th

21 ccelerated homologous desensitization of the leukotriene receptor and thereby terminated the oscillat

22 -lipoxygenase inhibition and sulfidopeptidyl leukotriene receptor antagonism on lumenal chemotaxis of

23 steroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) o

24 ment with ICSs alone (n = 1758) or ICSs plus leukotriene receptor antagonist (LTRAs; n = 354) or ICSs

25 ge in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticostero

26 ium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in

27 yclo-oxygenase inhibitor indomethacin or the leukotriene receptor antagonist MK-571, indicating that

28 o examine a potential protective role of the leukotriene receptor antagonist montelukast on future ri

29 ected animals with MC-stabilizing drugs or a leukotriene receptor antagonist restores vascular integr

30 ational method to titrate corticosteroid and leukotriene receptor antagonist therapy.

31 nist, long-acting muscarinic antagonist, and leukotriene receptor antagonist was hospitalized with a

32 choconstriction by a single oral dose of the leukotriene receptor antagonist zafirlukast was assessed

33 We aimed to assess whether montelukast, a leukotriene receptor antagonist, can improve symptoms or

34 vide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose sympt

35 he effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatment of pos

36 for a daily inhaled corticosteroid, a daily leukotriene receptor antagonist, or a mast cell stabiliz

37 Montelukast, an oral, once-daily leukotriene receptor antagonist, provides protection aga

38 ecommend an intranasal corticosteroid over a leukotriene receptor antagonist.

39 d be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.

40 leukotriene B4 receptor but not a cysteinyl-leukotriene receptor antagonist.

41 to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting beta2-agoni

42 fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up).

43 We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patient

44 roids (21.5%; 95% CI: 20.7%-22.3%; p<0.001), leukotriene receptor antagonists (13.4%; 95% CI: 12.9%-1

45 Long-acting beta2-agonists (LABA) and leukotriene receptor antagonists (LTRA) are two principa

46 The use of cysteinyl leukotriene receptor antagonists (LTRAs) for asthma ther

47 The growth of leukotriene receptor antagonists (LTRAs) has been extrao

48 Recent evidence suggests that the use of leukotriene receptor antagonists (LTRAs) in addition to

49 hieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection agai

50 Leukotriene receptor antagonists and long-acting beta2-a

51 osteroids [topical (swallowed) or systemic], leukotriene receptor antagonists and, most recently, bio

52 Controlled trials suggest that leukotriene receptor antagonists can improve lung functi

53 Oral leukotriene receptor antagonists have been shown to have

54 agents such as cromolyn and the new class of leukotriene receptor antagonists have demonstrated benef

55 ukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists have shown efficacy in

56 nical efficacy of inhaled glucocorticoids to leukotriene receptor antagonists in children with mild t

57 Leukotriene receptor antagonists such as montelukast hav

58 daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS trea

59 include daily inhaled corticosteroids, daily leukotriene receptor antagonists, and combination therap

60 s, long-acting inhaled beta2-stimulants, and leukotriene receptor antagonists, increased year after y

61 The leukotriene receptor antagonists, montelukast, zafirluka

62 the approved dose) plus H(2)-antihistamines, leukotriene receptor antagonists, or both.

63 the approved dose plus H(2)-antihistamines, leukotriene receptor antagonists, or both.

64 useful add-on therapies for AR include oral leukotriene receptor antagonists, short bursts of a nasa

65 emists in the design of potent and selective leukotriene receptor antagonists-leukotriene structural

66 mple, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.

67 ticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists.

68 successfully identified clinically effective leukotriene receptor antagonists.

69 ay disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmac

70 Leukotriene-receptor antagonists (LTRAs) are recommended

71 Leukotriene-receptor antagonists are the first novel cla

72 Leukotriene-receptor antagonists as monotherapy improved

73 Leukotriene-receptor antagonists either as monotherapy o

74 Another potential spin-off of leukotriene-receptor antagonists is that they also seem

75 The published data with leukotriene-receptor antagonists such as montelukast or

76 long-acting beta agonists, theophyllines, or leukotriene-receptor antagonists, adjusted stepwise acco

77 Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT(1)R) are efficacious for bro

78 and human fibrocytes express both cysteinyl leukotriene receptor (CysLT) 1 and CysLT2.

79 Two classes of cysteinyl leukotriene receptor, CysLT(1) and CysLT(2), have been i

80 and characterization of the second cysteinyl leukotriene receptor, CysLT(2), a 346-amino acid protein

81 enes C4 associated with an overexpression of leukotrienes receptor CysLTR1 by asthmatic BSM cells in

82 kotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) contribute t

83 and a total absence of disease pathology in leukotriene receptor-deficient mice.

84 Here we show that abolishing leukotriene receptor desensitization suppresses agonist-

85 s of diabetes for retinal histopathology and leukotriene receptor expression and 2) after 3 months of

86 Finally, leukotrienes receptor expression was assessed in vitro b

87 s the way for future clinical translation of leukotriene receptor inhibition for the treatment of dem

88 blotting for gene and protein expression of leukotriene receptors LT1-R and LT2-R, and for concentra

89 dministration has issued safety alerts about leukotriene receptor-modifying agents and suicidality/su

90 ing to replenish the PIP2 pool accessible to leukotriene receptors, ostensibly through control of PIP

91 a marketed anti-asthmatic drug antagonizing leukotriene receptors, reduces neuroinflammation, elevat

92 therosclerosis is associated with a specific leukotriene receptor(s) capable of inducing hyperreactiv

93 This work illustrates that inhibition of leukotriene receptor signalling might represent a safe a

94 erized the gene structure of human cysteinyl leukotriene receptor type I (cysLT(1)R).

95 The expression of leukotriene receptors was deregulated in esophageal squa

96 Leukotriene receptors were examined by autoradiography,

97 ajor findings were: 1) protein levels of all leukotriene receptors were significantly increased in es